Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.
Authors not listed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2000
Abstract
The purpose of this study is to evaluate the efficacy and safety of risperidone compared with placebo in the treatment of psychotic symptoms in patients with Alzheimer's disease
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2000). Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease. <em>Johnson & Johnson Pharmaceutical Research & Development, L.L.C.</em>. https://clinicaltrials.gov/study/NCT00034762
Vancouver
Anonymous. Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 2000.
BibTeX
@misc{anon2000Effica,
title = {Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.},
author = {Anonymous},
journal = {Johnson & Johnson Pharmaceutical Research & Development, L.L.C.},
year = {2000},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 1997
Open access · US-GOV
Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial
Avanir Pharmaceuticals 2012
Open access · US-GOV
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2001
Open access · US-GOV
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
Bristol-Myers Squibb 2025
Open access · US-GOV
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 2)
AbbVie (prior sponsor, Abbott) 2009
Open access · US-GOV
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease
AbbVie (prior sponsor, Abbott) 2009
Open access · US-GOV